CD8A and metastatic melanoma: Also, patients with metastatic melanoma responding to CTLA-4 inhibition but not to anti-PD1 therapy had a higher ratio of circulating CCR7- CD45RO+ CD8+ Tem cells compared to baseline (≥30% of total circulating CD8+ cells) [76].